RE:RE:RE:RE:RE:Repurchases so far from NCIBMrMugsy wrote: Eoj123 wrote: I'm sure glad I sold this about a half a dozen years ago shorly after they sold their priority review voucher and just after their run to $10. It's been a dog since
Well done EOJ.
You don't hold these shares unless you're doing it the way you did it with Paladin.
Only a handful of investors here - accumulating for the long-term.
What did I say ... ~60 investors (give or take) holding 70% of the company.
Tough to say how many own the remaining 30% - but let's call about half of them transient.
And ... the biggest moves that really rock the price won't happen for a while.
You either prepare for it - you wait to join later - or you simply just ignore this one and focus on other things. Obviously, most of the investing world will just ignore this one.
This will only have a cult following until it doesn't anymore.
When is that ?
Wouldn't even try to guess.
Not much new info since last Q results. What do you watch until next Q ?
Do we have clues about Exelon sales once they did the transition with Novartis ?
GUD expertise is to market unpromoted products. Should ne interesting to see if they get sales growth with the larger pipeline